Kantonsspital St.Gallen

Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer

Hans Tesch, Volkmar Müller, Achim Wöckel, Johannes Ettl, Erik Belleville, Florian Schütz, Andreas Hartkopf, Marc Thill, Jens Huober, Peter A Fasching, Hans-Christian Kolberg, Carla E Schulmeyer, Manfred Welslau, Friedrich Overkamp, Tanja N Fehm, Michael P Lux, Andreas Schneeweiss, Diana Lüftner & Wolfgang Janni

abstract Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a mutation. The treatment of patients with a or mutation has also been improved by the introduction of PARP inhibitors. Attempts are now being made increasingly to extend treatment indications based on molecular patterns, to identify other patients who could benefit from a treatment and to integrate the newly established treatment methods in existing therapy sequences. This review articles summarises the latest information in this connection.
citation Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching P A, Kolberg H C, Schulmeyer C E, Welslau M, Overkamp F, Fehm T N, Lux M P, Schneeweiss A, Lüftner D, Janni W. Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80:1115-1122.
type journal paper/review (English)
date of publishing 06-11-2020
journal title Geburtshilfe Frauenheilkd (80/11)
ISSN print 0016-5751
pages 1115-1122
PubMed 33173239
DOI 10.1055/a-1270-7481